Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have been given an average rating of “Moderate Buy” by the five research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $7.40.

A number of brokerages have recently weighed in on ATNM. StockNews.com lowered Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Stephens reiterated an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, November 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Interchange Capital Partners LLC bought a new position in shares of Actinium Pharmaceuticals during the 3rd quarter valued at about $37,000. Barclays PLC lifted its stake in Actinium Pharmaceuticals by 323.0% in the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after buying an additional 32,784 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Actinium Pharmaceuticals in the second quarter valued at approximately $92,000. Wellington Management Group LLP acquired a new position in shares of Actinium Pharmaceuticals in the third quarter valued at approximately $112,000. Finally, Creative Financial Designs Inc. ADV increased its position in shares of Actinium Pharmaceuticals by 183.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock worth $120,000 after acquiring an additional 41,250 shares in the last quarter. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Performance

Shares of NYSE:ATNM opened at $1.36 on Friday. Actinium Pharmaceuticals has a twelve month low of $1.19 and a twelve month high of $10.24. The firm has a market capitalization of $42.43 million, a price-to-earnings ratio of -0.98 and a beta of 0.07. The firm has a fifty day simple moving average of $1.66.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).